Mentored Patient Oriented Research in Lymphoma

以患者为导向的淋巴瘤研究指导

• 批准号: 10071361
• 负责人: CHRISTOPHER R FLOWERS
• 金额: $ 14.78万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10071361
• 关键词: Mentored; Patient; Oriented; Research; Lymphoma

PROJECT SUMMARY Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma in the US, affects ~22,000 people/year and is a significant clinical problem for cancer patient-oriented research in that it is a curable disease, but one with heterogeneous outcomes. Despite >58% of patients being alive and cured at 5 years with modern chemo- immunotherapy, outcomes are significantly worse for patients who are African American (AA), uninsured, or those who have activated B-cell-like (ABC) biological subtype or a high international prognostic index score. Dr. Flowers has described patient outcomes for biological subtypes of DLBCL, identified racial and socioeconomic disparities in DLBCL, and modeled how race/ethnicity, biological, and socioeconomic factors interact to influence DLBCL survival. However, at present there is no unifying, comprehensive prognostic system that incorporates these parameters. To address the current and long-term unmet health needs of the lymphoma patient population, Drs. Flowers and Cerhan established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (U01CA195568), which will support a broad research agenda aimed at identifying novel clinical, epidemiologic, host genetic, tumor, and treatment factors that significantly influence prognosis and survivorship. LEO will: 1) Recruit >12,000 newly diagnosed lymphoma patients (including 1,000 AA and 1,400 Hispanic participants and 3,700 DLBCLs); 2) Build a tissue bank with extracted tumor DNA and RNA, peripheral blood DNA, serum and plasma; 3) Annotate all cases with clinical, epidemiologic, pathology, and treatment data; 4) Prospectively follow patients to ascertain disease progression/relapse, retreatment, second cancers, survival, and patient-reported outcomes; and 5) Facilitate research projects that use this infrastructure. In addition, Dr. Flowers will utilize LEO protocols and the Georgia state SEER registry to construct a population-based cancer disparities cohort study that will: 1) examine the relationships between DLBCL genomics, ABC subtype, race, pattern of presentation, treatment and survival; 2) develop a computer micro-simulation model that incorporates these data into an online prognostic tool for DLBCL as a decision support tool for patients, clinicians, and other investigators. Dr. Flowers will build on his national leadership on the American Society Hematology Committee on Promoting Diversity, American Society Clinical Oncology Health Disparities Committee, and in clinical research mentorship programs for ASH and the Lymphoma Research Foundation and utilize these resources to recruit, train, and develop a cadre of junior faculty, hematology/oncology fellows, housestaff, and medical students in cancer patient-oriented research with a particular focus on developing minority investigators who will lead the field.

项目摘要 弥漫性大B细胞淋巴瘤（DLBCL）是美国最常见的淋巴瘤，影响约22,000人/年 对于癌症以患者为导向的研究是一种可治愈的疾病，这是一个重大的临床问题，但是 与异质结果。尽管有58％的患者活着并治愈了5年，现代化学疗法 对于非裔美国人（AA），未保险或 那些激活了类似B细胞（ABC）生物亚型或高国际预后指数评分的人。 Flowers博士描述了DLBCL生物亚型的患者结果，确定的种族和 DLBCL中的社会经济差异，并建立了种族/种族，生物学和社会经济因素的模型 相互作用以影响DLBCL生存。但是，目前尚无统一，全面的预后 包含这些参数的系统。满足当前和长期未满足的健康需求 淋巴瘤患者人群，Drs。 Flowers和Cerhan建立了结局的淋巴瘤流行病学 （LEO）队列研究（U01CA195568），该研究将支持旨在识别新颖的研究议程 临床，流行病学，宿主遗传，肿瘤和治疗因素，显着影响预后和 生存。狮子座将：1）招募> 12,000名新诊断的淋巴瘤患者（包括1,000 AA和1,400例 西班牙裔参与者和3,700个DLBCL）； 2）用提取的肿瘤DNA和RNA构建组织库， 外周血DNA，血清和血浆； 3）注释所有临床，流行病学，病理学和 治疗数据； 4）前瞻性跟随患者确定疾病进展/复发，退缩，第二 癌症，生存和患者报告的结果； 5）促进使用此项的研究项目 基础设施。此外，Flowers博士将利用LEO协议和佐治亚州SEER注册表 构建基于人群的癌症差异队列研究，该研究将：1）检查 DLBCL基因组学，ABC亚型，种族，表现方式，治疗和生存模式； 2）开发电脑 微模拟模型将这些数据纳入DLBCL的在线预后工具作为决定 患者，临床医生和其他研究人员的支持工具。鲜花博士将建立在他的国家领导的基础上 美国社会促进多样性的血液学委员会，美国社会临床肿瘤学 健康差异委员会，以及针对ASH和淋巴瘤的临床研究指导计划 研究基金会并利用这些资源来招募，培训和发展初级教师干部， 血液学/肿瘤学研究员，Housestaff和医学生以患者为导向的研究 特别关注将领导该领域的少数族裔调查员。